5 withdrawn. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Withdrawn 5 |
| Phase 2 | 2 | Withdrawn 2 |
Follow niraparib: new trials by email Literature Review of niraparib trials Research Report on niraparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Biopsy, Biospecimen Collection, Niraparib - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-18 | 2025-05-23 | |
| ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors ZEN003694, Niraparib - Ovarian Cancer, Recurrent Solid Tumors | Phase 1 | Withdrawn | Haider Mahdi | 2024-01-23 | 2024-10-15 | |
| Reirradiation and Niraparib in Patients With Recurrent Glioblastoma Niraparib, Re-irradiation (re-RT) - Recurrent Glioblastoma | Phase 1 | Withdrawn | University College, London | 2023-10-13 | 2024-03-26 | |
| LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer Niraparib, Doxorubicin, Cyclophosphamide - Breast Cancer | Phase 1 | Withdrawn | Wake Forest University Health Sciences | 2021-04-01 | 2022-04-26 | |
| Study of M4344 in Combination With Niraparib Niraparib, M4344 - Advanced Solid Tumor, Breast Cancer | Phase 1 / Phase 2 | Withdrawn | EMD Serono Research & Development Institute, Inc. | 2020-12-01 | 2021-06-30 |
Breast Neoplasms (2) · Ovarian Neoplasms (2) · Fallopian Tube Neoplasms (1) · Glioblastoma (1)
City of Hope Medical Center (1) · EMD Serono Research & Development Institute, Inc. (1) · Haider Mahdi (1) · University College, London (1) · Wake Forest University Health Sciences (1)
United States (1)
Antoinette Tan, MD (1) · Dusan Milanovic (1) · Haider S Mahdi, MD (1) · Lorna Rodriguez-Rodriguez (1)
P30CA033572 (1)